Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alpha1-adrenoceptors and ejaculatory function.

M C Michel1

  • 1Department of Pharmacology & Pharmacotherapy, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. m.c.michel@amc.nl

British Journal of Pharmacology
|July 3, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Management of geriatric patients with benign prostatic hyperplasia].

Der Urologe. Ausg. A·2020
Same author

[Do benign prostatic hyperplasia drugs affect mood or cognition?]

Der Urologe. Ausg. A·2019
Same author

An observational study of patient satisfaction with fesoterodine in the treatment of overactive bladder: effects of additional educational material.

International journal of clinical practice·2014
Same author

The Concise Guide to PHARMACOLOGY 2013/14: overview.

British journal of pharmacology·2014
Same author

Does concomitant diabetes affect treatment responses in overactive bladder patients?

International journal of clinical practice·2013
Same author

Autonomic nervous control of the urinary bladder.

Acta physiologica (Oxford, England)·2012
Same journal

Fangchinoline alleviates hypertensive heart failure via PGC-1α/STAT6/PPARγ activation of mitophagy against ferroptosis.

British journal of pharmacology·2026
Same journal

The selective degradation of PDE4B shortform, using a PROTAC, leads to inhibition of several hallmarks of cancer in HCT116 cells.

British journal of pharmacology·2026
Same journal

Immune checkpoint inhibitor-induced arrhythmias: Mechanistic insights from clinical and preclinical studies.

British journal of pharmacology·2026
Same journal

Leflunomide-inhibited STAT1 activity ameliorates intramuscular M1 macrophage infiltration and promotes muscle regeneration in Duchenne muscular dystrophy.

British journal of pharmacology·2026
Same journal

Pharmacological activation of NO-cGMP signalling attenuates metabolic dysfunction-associated steatohepatitis.

British journal of pharmacology·2026
Same journal

Inhibition of kynurenine 3-monooxygenase (KMO) reduces fentanyl and sucrose intake and relapse-like behaviour in rats.

British journal of pharmacology·2026
See all related articles

Alpha(1)-adrenoceptor antagonists like silodosin can cause abnormal ejaculation. A new study in knockout mice reveals impaired vas deferens function, not sperm issues, as the cause of reduced ejaculation and male infertility.

Area of Science:

  • Pharmacology
  • Urology
  • Reproductive Biology

Background:

  • Alpha(1)-adrenoceptor antagonists, particularly selective alpha(1A)-adrenoceptor antagonists (e.g., silodosin, tamsulosin), are associated with abnormal ejaculation, often anejaculation.
  • Recent research suggests this side effect stems from impaired vas deferens function rather than altered sperm parameters.

Discussion:

  • A study utilizing alpha(1A) single and alpha(1A/B/D) triple knockout mice models the abnormal ejaculation observed in humans.
  • The research elucidates that the underlying cause is impaired contractility of the vas deferens, impacting semen expulsion.
  • Differences in receptor subtype involvement between mice and humans are highlighted, explaining varied drug efficacies.

Key Insights:

  • Reduced ejaculation and male infertility linked to alpha(1)-adrenoceptor antagonist use are primarily due to vas deferens dysfunction.

Related Experiment Videos

  • Sperm formation, count, and function remain unaffected, ruling them out as causes of ejaculatory disorders.
  • Rodent models successfully replicate human clinical observations regarding drug-induced ejaculatory dysfunction.

    • Outlook:

    • Further investigation into the specific mechanisms of vas deferens dysfunction caused by alpha(1)-adrenoceptor antagonists.
    • Development of therapeutic strategies to mitigate or reverse ejaculatory side effects of these medications.
    • Comparative studies to fully delineate the role of different alpha(1)-adrenoceptor subtypes in human and rodent ejaculatory physiology.